These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Humoral immunity to SARS-CoV-2 in kidney transplant recipients and dialysis patients: IgA and IgG patterns unraveled after SARS-CoV-2 infection and vaccination. De Bouver C; Bouziotis J; Wijtvliet VPWM; Ariën KK; Mariën J; Heyndrickx L; Couttenye MM; de Fijter HJW; Mestrez F; Treille S; Mat O; Collart F; Allard SD; Vingerhoets L; Moons P; Abramowicz D; De Winter BY; Pipeleers L; Wissing KM; Ledeganck KJ Virol J; 2024 Jun; 21(1):138. PubMed ID: 38872127 [TBL] [Abstract][Full Text] [Related]
6. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675 [TBL] [Abstract][Full Text] [Related]
7. BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus. Moyon Q; Sterlin D; Miyara M; Anna F; Mathian A; Lhote R; Ghillani-Dalbin P; Breillat P; Mudumba S; de Alba S; Cohen-Aubart F; Haroche J; Pha M; Boutin THD; Chaieb H; Flores PM; Charneau P; Gorochov G; Amoura Z Ann Rheum Dis; 2022 Apr; 81(4):575-583. PubMed ID: 34607791 [TBL] [Abstract][Full Text] [Related]
8. Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis. Strengert M; Becker M; Ramos GM; Dulovic A; Gruber J; Juengling J; Lürken K; Beigel A; Wrenger E; Lonnemann G; Cossmann A; Stankov MV; Dopfer-Jablonka A; Kaiser PD; Traenkle B; Rothbauer U; Krause G; Schneiderhan-Marra N; Behrens GMN EBioMedicine; 2021 Aug; 70():103524. PubMed ID: 34391096 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay. Nam M; Seo JD; Moon HW; Kim H; Hur M; Yun YM Microbiol Spectr; 2021 Dec; 9(3):e0120221. PubMed ID: 34817223 [TBL] [Abstract][Full Text] [Related]
10. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting. Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J Front Immunol; 2021; 12():802858. PubMed ID: 35003131 [TBL] [Abstract][Full Text] [Related]
11. Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease. Malipiero G; Moratto A; Infantino M; D'Agaro P; Piscianz E; Manfredi M; Grossi V; Benvenuti E; Bulgaresi M; Benucci M; Villalta D Immunol Res; 2021 Dec; 69(6):576-583. PubMed ID: 34417958 [TBL] [Abstract][Full Text] [Related]
13. Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies. Amodio D; Ruggiero A; Sgrulletti M; Pighi C; Cotugno N; Medri C; Morrocchi E; Colagrossi L; Russo C; Zaffina S; Di Matteo G; Cifaldi C; Di Cesare S; Rivalta B; Pacillo L; Santilli V; Giancotta C; Manno EC; Ciofi Degli Atti M; Raponi M; Rossi P; Finocchi A; Cancrini C; Perno CF; Moschese V; Palma P Front Immunol; 2021; 12():727850. PubMed ID: 34671350 [TBL] [Abstract][Full Text] [Related]
14. Humoral immune response against SARS-CoV-2 after adapted COVID-19 vaccine schedules in healthy adults: The IMCOVAS randomized clinical trial. Steenackers K; Hanning N; Bruckers L; Desombere I; Marchant A; Ariën KK; Georges D; Soentjens P; D'Onofrio V; Hites M; Berens-Riha N; De Coster I; Damme PV Vaccine; 2024 Nov; 42(25):126117. PubMed ID: 39019657 [TBL] [Abstract][Full Text] [Related]
15. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days. Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R Front Immunol; 2021; 12():726960. PubMed ID: 34671348 [TBL] [Abstract][Full Text] [Related]